PMC6666367_01
Response of a metastatic adenocarcinoma patient to dabrafenib and trametinib. The red arrows indicate the reduced mass.
OTT-12-6045-g0005.jpg
PMC6666367_01_OTT-12-6045-g0005.jpg
F0005
However, subsequent treatment with dabrafenib and trametinib after three previous lines of chemotherapy resulted in regression of the tumor after one month (Figure 5).